Rocket Lab Raises Funds To Prepare For Closing Of Iridium Acquisition

Rocket Lab completed a $1.94 billion at-the-market equity offering, issuing 29.3 million shares, and said the proceeds plus existing cash fully fund its proposed Iridium acquisition and certain debt repayment. The company also amended its $1.77 billion credit facility and canceled a previously arranged $3.6 billion bridge loan, reducing financing uncertainty ahead of an expected mid-2027 closing. Management views Iridium as a transformational addition that would expand Rocket Lab from launch and satellite manufacturing into integrated space applications, although the company remains unprofitable while funding Neutron development.

Analysis

The financing removes the most acute deal-break risk, but it replaces it with a valuation problem: RKLB has effectively prepaid for a 2027-close asset while assuming execution, regulatory, and integration risk for roughly 18 months. Cancellation of bridge financing reduces interest-rate and refinancing exposure, yet the equity issuance raises the hurdle for per-share accretion; the relevant question is whether Iridium’s contracted service revenue and spectrum optionality can offset dilution before Neutron begins consuming incremental capital. Near term, this should tighten the IRDM merger-arbitrage spread, while RKLB’s reaction may be capped by prospective follow-on issuance if management pursues the stated acquisition pipeline.

The strategic upside is not launch revenue but vertical ownership of recurring connectivity cash flows, which could lower customer-acquisition costs for future constellation operators and improve utilization of Rocket Lab’s spacecraft components. The less appreciated loser is AST SpaceMobile (ASTS): a scaled RKLB/IRDM platform could become a better-capitalized alternative partner for direct-to-device and defense communications customers, although Iridium’s narrowband network is not a direct substitute for ASTS broadband. Defense-adjacent peers such as L3Harris (LHX) and Viasat (VSAT) face longer-term competitive pressure if the combined company packages sovereign communications, spacecraft production, and launch under one procurement relationship.

Consensus is likely to extrapolate a de-risked financing event into a de-risked equity. It is not: the central catalyst remains Neutron test performance, and a delay would defer the stated EBITDA/cash-flow inflection while increasing the chance that the acquired cash-generative asset subsidizes launch development. Falsify the cautious view if Neutron stays on schedule, IRDM’s standalone service revenue and EBITDA guidance are reaffirmed through closing, and management quantifies post-close cost/revenue synergies sufficient to make the transaction accretive on a per-share FCF basis within 24-36 months.

Key Decisions for Investors

• Maintain a merger-arbitrage long IRDM position only if the discount to implied consideration exceeds estimated 18-month carry plus a meaningful regulatory-risk premium; target the September 24 shareholder vote as the first catalyst, but size for a mid-2027 closing and potential spectrum/national-security review delays.
• Do not chase RKLB on financing completion. Use strength to reduce tactical exposure; re-enter only after a disclosed Neutron test-date milestone or a material pullback that restores asymmetric upside. Risk is further dilution or a test slip; upside requires credible per-share FCF accretion, not merely deal completion.
• Express relative caution through long IRDM / short RKLB in equal deal-value-adjusted notional until definitive consideration mechanics, exchange ratio, and regulatory timetable are independently verified. This isolates closing/spread compression from RKLB’s pre-close Neutron and capital-allocation volatility.
• Put ASTS on a 6-18 month competitive watch rather than shorting immediately. Escalate only if the combined company announces direct-to-device spectrum partnerships or a funded broadband constellation; that would challenge ASTS’s strategic scarcity premium and could compress its valuation multiple.
• Monitor RKLB quarterly for cash burn, Neutron capex, and any acquisition discussion before closing. A material increase in launch-development spending or another equity authorization without quantified IRDM synergies invalidates the per-share value-creation case.